Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS DRUG INDUSTRY
2.1 Summary about Focal Segmental Glomerulosclerosis Drug Industry
2.2 Focal Segmental Glomerulosclerosis Drug Market Trends
2.2.1 Focal Segmental Glomerulosclerosis Drug Production & Consumption Trends
2.2.2 Focal Segmental Glomerulosclerosis Drug Demand Structure Trends
2.3 Focal Segmental Glomerulosclerosis Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Losmapimod
4.2.2 SHP-627
4.2.3 Sparsentan
4.2.4 TM-5484
4.2.5 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Clinic
4.3.2 Research Center
4.3.3 Hospital
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Losmapimod
5.2.2 SHP-627
5.2.3 Sparsentan
5.2.4 TM-5484
5.2.5 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Clinic
5.3.2 Research Center
5.3.3 Hospital
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Losmapimod
6.2.2 SHP-627
6.2.3 Sparsentan
6.2.4 TM-5484
6.2.5 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Clinic
6.3.2 Research Center
6.3.3 Hospital
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Losmapimod
7.2.2 SHP-627
7.2.3 Sparsentan
7.2.4 TM-5484
7.2.5 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Clinic
7.3.2 Research Center
7.3.3 Hospital
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Losmapimod
8.2.2 SHP-627
8.2.3 Sparsentan
8.2.4 TM-5484
8.2.5 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Clinic
8.3.2 Research Center
8.3.3 Hospital
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Losmapimod
9.2.2 SHP-627
9.2.3 Sparsentan
9.2.4 TM-5484
9.2.5 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Clinic
9.3.2 Research Center
9.3.3 Hospital
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Complexa Inc
10.1.2 Dimerix Bioscience Pty Ltd
10.1.3 GlaxoSmithKline Plc
10.1.4 Retrophin Inc
10.1.5 Shire Plc
10.1.6 Variant Pharmaceuticals Inc
10.2 Focal Segmental Glomerulosclerosis Drug Sales Date of Major Players (2017-2020e)
10.2.1 Complexa Inc
10.2.2 Dimerix Bioscience Pty Ltd
10.2.3 GlaxoSmithKline Plc
10.2.4 Retrophin Inc
10.2.5 Shire Plc
10.2.6 Variant Pharmaceuticals Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Focal Segmental Glomerulosclerosis Drug Product Type Overview
Table Focal Segmental Glomerulosclerosis Drug Product Type Market Share List
Table Focal Segmental Glomerulosclerosis Drug Product Type of Major Players
Table Brief Introduction of Complexa Inc
Table Brief Introduction of Dimerix Bioscience Pty Ltd
Table Brief Introduction of GlaxoSmithKline Plc
Table Brief Introduction of Retrophin Inc
Table Brief Introduction of Shire Plc
Table Brief Introduction of Variant Pharmaceuticals Inc
Table Products & Services of Complexa Inc
Table Products & Services of Dimerix Bioscience Pty Ltd
Table Products & Services of GlaxoSmithKline Plc
Table Products & Services of Retrophin Inc
Table Products & Services of Shire Plc
Table Products & Services of Variant Pharmaceuticals Inc
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Focal Segmental Glomerulosclerosis Drug Market Forecast (Million USD) by Region 2021f-2026f
Table Global Focal Segmental Glomerulosclerosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Focal Segmental Glomerulosclerosis Drug Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Focal Segmental Glomerulosclerosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f